1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 16 (Search time: 0.001 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012The experience of patients with advanced chronic obstructive pulmonary disease and advance care-planning: a South Australian perspectiveBrown, M.; Brooksbank, M.; Burgess, T.; Young, M.; Crawford, G.
2014Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinomaAl-Ejeh, F.; Pajic, M.; Shi, W.; Kalimutho, M.; Miranda, M.; Nagrial, A.; Chou, A.; Biankin, A.; Grimmond, S.; Brown, M.; Khanna, K.
2014Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Falchook, G.; Long, G.; Kurzrock, R.; Kim, K.; Arkenau, H.; Brown, M.; Hamid, O.; Infante, J.; Millward, M.; Pavlick, A.; Chin, M.; O'Day, S.; Blackman, S.; Curtis, C.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R.
2014An immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3Zochling, J.; Newell, F.; Charlesworth, J.; Leo, P.; Stankovich, J.; Cortes, A.; Zhou, Y.; Stevens, W.; Sahhar, J.; Roddy, J.; Nash, P.; Tymms, K.; Rischmueller, M.; Lester, S.; Proudman, S.; Brown, M.
2014Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profilingPishas, K.; Neuhaus, S.; Clayer, M.; Schreiber, A.; Lawrence, D.; Perugini, M.; Whitfield, R.; Farshid, G.; Manavis, J.; Chryssidis, S.; Mayo, B.; Haycox, R.; Ho, K.; Brown, M.; D'Andrea, R.; Evdokiou, A.; Thomas, D.; Desai, J.; Callen, D.; Neilsen, P.
2013Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)Nathanson, K.; Martin, A.; Wubbenhorst, B.; Greshock, J.; Letrero, R.; D'Andrea, K.; O'Day, S.; Infante, J.; Falchook, G.; Arkenau, T.; Millward, M.; Brown, M.; Pavlick, A.; Davies, M.; Ma, B.; Gagnon, R.; Curtis, M.; Lebowitz, P.; Kefford, R.; Long, G.
2016GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockadeGargett, T.; Yu, W.; Dotti, G.; Yvon, E.; Christo, S.; Hayball, J.; Lewis, I.; Brenner, M.; Brown, M.
2011Breast cancer stem cells: treatment resistance and therapeutic opportunitiesAl-ejeh, F.; Smart, C.; Morrison, B.; Chenevix-Trench, G.; Lopez, J.; Lakhani, S.; Brown, M.; Khanna, K.
2013Unmet needs of people with end-stage chronic obstructive pulmonary disease: recommendations for change in AustraliaCrawford, G.; Brooksbank, M.; Brown, M.; Burgess, T.; Young, M.
2010Assessment of atrial septal defects in adults comparing cardiovascular magnetic resonance with transoesophageal echocardiographyTeo, K.; Disney, P.; Dundon, B.; Worthley, M.; Brown, M.; Sanders, P.; Worthley, S.

Discover